Ieq Capital LLC Buys 31,641 Shares of DexCom, Inc. (NASDAQ:DXCM)

Ieq Capital LLC increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 149.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 52,744 shares of the medical device company’s stock after acquiring an additional 31,641 shares during the period. Ieq Capital LLC’s holdings in DexCom were worth $4,102,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Principal Securities Inc. raised its stake in DexCom by 3.4% in the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock worth $316,000 after buying an additional 135 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in DexCom by 1.0% in the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after buying an additional 182 shares in the last quarter. GPS Wealth Strategies Group LLC raised its stake in DexCom by 13.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock worth $123,000 after buying an additional 185 shares in the last quarter. Peterson Wealth Services increased its stake in shares of DexCom by 7.1% during the fourth quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock valued at $236,000 after purchasing an additional 201 shares in the last quarter. Finally, Magnolia Capital Advisors LLC increased its stake in shares of DexCom by 2.6% during the fourth quarter. Magnolia Capital Advisors LLC now owns 8,198 shares of the medical device company’s stock valued at $638,000 after purchasing an additional 210 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

DXCM has been the subject of a number of analyst reports. Royal Bank of Canada decreased their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Sanford C. Bernstein raised their target price on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and raised their target price for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Citigroup raised their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $99.06.

Insider Buying and Selling

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is owned by insiders.

DexCom Trading Down 0.6 %

Shares of DXCM stock opened at $88.78 on Friday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The firm’s 50 day moving average is $83.26 and its 200 day moving average is $75.94. The stock has a market capitalization of $34.69 billion, a P/E ratio of 62.08, a P/E/G ratio of 2.31 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.